Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

1471 - Prognostic factor analysis for elderly patients treated for metastatic colorectal cancer in the randomized phase II trial PRODIGE 20


08 Oct 2016


Poster Display


thomas Aparicio


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


T. Aparicio1, O. Bouché2, E. Francois3, E. Maillard4, S. Kirscher5, J. Taieb6, P. Etienne7, R. Faroux8, F. Khemissa Akouz9, F. El Hajbi10, C. Locher11, Y. Rinaldi12, T. Lecomte13, S. Lavau-Denes14, M. Baconnier15, A. Oden-Gangloff16, D. Genet17, E. Paillaud18, F. Retornaz19, L. Bedenne20

Author affiliations

  • 1 Service Hge, Hôpital Avicenne - AP-HP, 93000 - Bobigny/FR
  • 2 Médecine Ambulatoire-cancérologie, CHU Robert Debré, Reims/FR
  • 3 Service Oncologie, Centre Antoine Lacassagne, Nice/FR
  • 4 Faculté De Médecine, FFCD, 21079 - Dijon/FR
  • 5 -, Institut Ste Catherine, Avignon/FR
  • 6 Service Hge, Hôpital européen G.Pompidou, Paris/FR
  • 7 Service Oncologie, Centre CARIO - HPCA, Plerin sur mer/FR
  • 8 Service D'hge, CHD Vendee - Hopital Les Oudairies, 85925 - La Roche sur Yon/FR
  • 9 Service Hge, CH Saint Jean, Perpignan/FR
  • 10 Service Cancérologie Digestive, Centre Oscar Lambret, 59037 - Lille/FR
  • 11 Service Gastroentérologie, CH de Meaux, 77100 - Meaux/FR
  • 12 Service D'hge, Hôpital européen, Marseille/FR
  • 13 Service Hge, Hôpital Trousseau, Tours/FR
  • 14 Service D'oncologie, CHU Limoges - Hopital Dupuytren, 87042 - Limoges/FR
  • 15 Service Hge, CH Annecy Genevois, 74374 - Pringy/FR
  • 16 Service Hge, CHU Charles Nicolle, 76031 - Rouen/FR
  • 17 Service Oncologie, Clinique Chenieux, Limoges/FR
  • 18 Service Médecine Interne Et Gériatrie, CHU Henri Mondor, Créteil/FR
  • 19 -, Hôpital européen, Marseille/FR
  • 20 Service Hge, CHU Le Bocage, INSERM U866, Dijon/FR


Abstract 1471


PRODIGE 20 randomized patients (pts) aged 75+ to receive bevacizumab + chemotherapy (LV5FU2, FOLFOX, FOLFIRI, according investigators choice) or chemotherapy alone. The primary endpoint based on efficacy and safety was reached in BEV-CT. This analysis presents updated progression-free survival (PFS) and overall survival (OS), including univariate and multivariate analyses.


PFS was defined as time from randomization to progression or death and OS as time from randomization to death. Prognostic factors analyzed were: treatment arm, age (≤80 vs >80), sex, rectum vs colon, primary tumor resected or not, doublet vs mono-chemotherapy, body mass index (≥21 vs 2N vs ≤2N), CA19.9 (>2N vs ≤2N) and Köhne criteria (low vs intermediate vs high). Baseline variables significant at 15% in univariate analysis were introduced in the multivariate Cox model.


102 pts were randomized (51 BEV-CT, 51 CT) and 100 pts were treated: chemotherapy was LV5FU2 in 52 pts (26 BEV-CT, 26 CT) and a doublet regimen in 48 pts (23 BEV-CT, 25 CT) including 23 FOLFOX and 25 FOLFIRI. The median follow-up was 20.4 months. 25 pts BEV-CT and 31 pts CT received 2nde line chemotherapy. Multivariate analysis shows that Spitzer QoL, albumin and Köhne criteria were prognostic for OS. Spitzer QoL and Köhne criteria were also prognostic for PFS.

CT [95% CI] BEV + CT [95% CI]
Median PFS (m) 7.8 [6.6-10.2] 9.7 [8.2-12.0]
12 months PFS rate 23.5% [13.0-35.8] 37.3% [24.3-50.2]
Median OS (m) 19.8 [13.9-23.7] 21.7 [14.8-30.3]
36 months OS rate 10.1% [3.1-22.0] 27.0% [15.7-39.7]


Spitzer QoL and Köhne criteria are prognostic factors for OS and PFS and should be used as stratification factors in future trials in elderly pts. Pts with a prolonged OS were observed in BEV-CT.

Clinical trial identification


Legal entity responsible for the study

CHU Dijon


Programme Hospitalier de Recherche Clinique and Roche laboratory


T. Aparicio: Roche/Genentech, Sanofi, Ipsen, Novartis. O. Bouché: Merck Serono, Roche, Teva, Novartis, Lilly, Amgen, Pierre Fabre. E. Francois: Roche Pharma AG, Merck Serono, Roche Pharma AG, Sanofi, Celgène. J. Taieb: Roche Pharma AG. R. Faroux: Merck, Amgen. C. Locher: Merck Serono, Novartis, Roche Pharma AG, Sanofi. S. Lavau-Denes: Sanofi, AstraZeneca. L. Bedenne: Merck Serono, Roche Pharma AG. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings